BENEFIT–RISK ASSESSMENT OF UPADACITINIB TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Remo Panaccione 1
Irina Blumenstein 2
Peter Irving 3
Ramona Vladea 4
Dapo Ilo 4
Wen Zhou 4
Gweneth Levy 4
Xuan Yao 4
Iris Dotan 5
1 University of Calgary, Calgary, Canada
2 JW Goethe University Hospital, Frankfurt, Germany
3 Guy's and St Thomas' Hospital, London, United Kingdom
4 AbbVie Inc., North Chicago, United States
5 Tel Aviv University, Tel Aviv, Israel
Session
Clinical trials in IBD (Posters)
Conference
UEG Week 2022
Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]